Cargando…
Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery
INTRODUCTION: Advancement of novel anticancer drugs into clinical use is frequently halted by their lack of solubility, reduced stability under physiological conditions, and non-specific uptake by normal tissues, causing systemic toxicity. Their progress to use in the clinic could be accelerated by...
Autores principales: | Breen, Alastair F, Scurr, David, Cassioli, Maria Letizia, Wells, Geoffrey, Thomas, Neil R, Zhang, Jihong, Turyanska, Lyudmila, Bradshaw, Tracey D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901036/ https://www.ncbi.nlm.nih.gov/pubmed/31824148 http://dx.doi.org/10.2147/IJN.S226293 |
Ejemplares similares
-
Development of novel apoferritin formulations for antitumour benzothiazoles
por: Breen, Alastair F., et al.
Publicado: (2019) -
New Treatments in Renal Cancer: The AhR Ligands
por: Itkin, Boris, et al.
Publicado: (2020) -
Apoferritin encapsulation of cysteine protease inhibitors for cathepsin L inhibition in cancer cells
por: Quilles Junior, José C., et al.
Publicado: (2019) -
Apoferritin-Encapsulated Jerantinine A for Transferrin
Receptor Targeting and Enhanced Selectivity in Breast Cancer Therapy
por: Abuzaid, Haneen, et al.
Publicado: (2022) -
Listeria innocua Dps as a nanoplatform for bioluminescence based photodynamic therapy utilizing Gaussia princeps luciferase and zinc protoporphyrin IX
por: Al-Ani, Ali W., et al.
Publicado: (2019)